Antiprogestin Pharmacodynamics, Pharmacokinetics, and Metabolism: Implications for Their Long-Term Use

Graham Jang, G R Jang, Leslie Z. Benet, L Z Benet
Journal of pharmacokinetics and biopharmaceutics · 1997 · vol. 25(6) , pp. 647–672 · doi:10.1023/a:1025725716343 · PMID:9697076 · W1523650905
review OA: closed CC0 ⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This review discusses the pharmacodynamics, pharmacokinetics, and metabolism of mifepristone, lilopristone, and onapristone, including their interactions with CYP3A4 and P-glycoprotein.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Postcoital, Synthetic Estrenes Gonanes Hormone Antagonists Mifepristone Progestins Abortifacient Agents Abortifacient Agents Abortifacient Agents Adult ATP Binding Cassette Transporter, Subfamily B, Member 1 ATP Binding Cassette Transporter, Subfamily B, Member 1 Breast Neoplasms Breast Neoplasms Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital, Synthetic Endometriosis Endometriosis Estrenes Estrenes

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (3)

References (100)

Cited by (3)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0 · commercial use OK